Thanks to our Seed Grant Program, 16 ALS researchers now have up to $50,000 each to gather the preliminary data they need to propel their research in promising new directions, which can ultimately lead to new treatment options, approaches that optimize current care, or ways to help prevent ALS altogether.

The physical impact of living with ALS presents many challenges, especially as the disease progresses. With the help of assistive technologies, people living with ALS can maintain their independence and pursue their passions for as long as possible.

We urgently need more and better ALS treatments. Because of this, getting promising therapies out of the laboratory and into clinical testing as quickly as possible is key to making ALS a livable disease.

Our grandfather, Herbert Hoffman, died from ALS in February 1943. This was less than two years after Lou Gehrig passed away and his name became forever attached to this disease. We never knew our grandfather. But we knew and loved and treasured our time with our uncle, Hugh Hoffman. Our uncle’s incredible donation will be spent to expand access to existing multidisciplinary ALS clinics and to certify new ones. In addition, the donation will fund new and promising clinical trials.

February 11th marks the ninth annual International Day of Women and Girls in Science, which serves as an opportunity to recognize the achievements of women working in science, technology, engineering, and mathematics. To celebrate, we are shining a spotlight on Annie Collins, one of our 2023 Milton Safenowitz Postdoctoral Fellows, and how she is helping move the development of new ALS treatments forward.

The type of care that people with ALS receive affects survival and quality of life. That is why the ALS Association is committing nearly $2 million over the next two years to support research focused on optimizing the effectiveness, efficiency, and accessibility of ALS care. These funds, granted through the new Quality of Care Research Awards, will be distributed across five projects that focus on the health and care for people living with the disease.

There is an urgent need for new and improved therapies for ALS, as there is still no cure. To help accelerate drug development and get promising treatments one step closer to regulatory evaluation, the ALS Association has committed nearly $4 million to support four early-stage clinical trials through our Clinical Trial Awards.

While the number of ALS clinical trials has greatly expanded over the last five years, the number of people living with ALS participating in this research remains low and highly variable across trial sites. Our five 2023 Trial Capacity Award winners are working hard to eliminate barriers to trial participation.

Learn about the five bright, young researchers from prestigious academic institutions across the country who have been selected to join The ALS Association’s 2023 Class of Milton Safenowitz Postdoctoral Fellows.

In order to make ALS a livable disease and ultimately find a cure, we need to increase the number of clinical trials and make it easier for more people to participate in those trials. No one knows this better than Dr. Merit Cudkowicz, Director of the Sean M. Healey & AMG Center for ALS and Chief of Neurology at Massachusetts General Hospital.

Dr. Agessandro Abrahao, a professor of neurology at the University of Toronto and a neurologist at Sunnybrook Health Sciences Center, spoke about a new partnership between The ALS Association and the Focus Ultrasound Foundation and his work as a focused ultrasound investigator at the Harquail Centre for Neuromodulation.

We talked with including Dr. Kevin Rhine, a postdoctoral scholar at the University California San Diego, to learn more about his research, as well as his interests outside the lab.

We talked with Dr. Caiwei Guo, a postdoctoral fellow at the Stanford University School of Medicine, to learn more about her research, as well as her interests outside the lab.

We talked with Dr. Jayakrishna Shenoy, a postdoctoral research associate at Brown University, to learn more about his research, as well as his interests outside the lab.

Since 2019, The ALS Association Roundtable Program has provided a forum for candid, facilitated discussions that guide our strategy for ALS care, advocacy and research. Here are just a few examples of how Roundtable discussions have been turned into positive action for people living with ALS and their families.

On a recent Connecting ALS podcast episode, we spoke with Dr. Terry Heiman-Patterson, Professor of Neurology at the Lewis Katz School of Medicine at Temple University and Director of the Temple MDA/ALS Center of Hope, to learn more about her work looking into ways to expand access to clinical trials for historically underserved populations.

We talked with Dr. Miriam Linsenmeier, a postdoctoral fellow at the University of Pennsylvania’s Perelman School of Medicine, to learn more about her research, as well as her interests outside the lab.

Dr. Laura Ranum, director of the University of Florida’s Center for NeuroGenetics and the Kitzman Family Professor of Molecular Genetics and Microbiology, is currently conducting a phase 2 trial for C9orf72-linked familial ALS with support from the Association’s Clinical Trial Awards Program. 

This last year has seen incredible progress in the fight to create a world without ALS. The FDA approval of Relyvrio (AMX0035) in 2022 and Qalsody (tofersen) last month are significant steps in the effort to make ALS a livable disease. As we celebrate the success of these long-term investments, we continue to fund the next generation of possible treatments, as well as the researchers that are searching for them.

In March 2022, after several months of multiple doctor visits and many tests, Jacob Harper was diagnosed with P525L FUS ALS—a nano-rare version of ALS only found in people under the age of 25. Jacob is on the Jacifusen clinical trial trying to slow progression, as he shares his testimony with people from all over the world.